Compare · DXCM vs GMVD
DXCM vs GMVD
Side-by-side comparison of DexCom Inc. (DXCM) and G Medical Innovations Holdings Ltd. (GMVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GMVD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $30.16B, about 431.6x GMVD ($69.9M).
- DXCM has hit the wire 10 times in the past 4 weeks while GMVD has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for GMVD).
- Company
- DexCom Inc.
- G Medical Innovations Holdings Ltd.
- Price
- $82.30+3.04%
- $0.16-13.41%
- Market cap
- $30.16B
- $69.9M
- 1M return
- -4.53%
- -
- 1Y return
- +41.38%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
- Dexcom Reports Third Quarter 2026 Financial Results
- SEC Form 4 filed by DexCom Inc.
- Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- SEC Form 4 filed by DexCom Inc.
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
Latest GMVD
- SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form D filed by G Medical Innovations Holdings Ltd.
- SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)
- SEC Form 25-NSE filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.
- SEC Form 6-K filed by G Medical Innovations Holdings Ltd.